Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.
“These are the first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis,”...